# Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors

> **NCT06825156** · PHASE4 · COMPLETED · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 60 (actual)

## Conditions studied

- Acute Kidney Injury

## Interventions

- **DRUG:** Empagliflozin 10 MG

## Key facts

- **NCT ID:** NCT06825156
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-03
- **Primary completion:** 2023-05-26
- **Final completion:** 2023-05-26
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06825156

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06825156, "Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06825156. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*